Information:
Fel:
ID
34292
Beskrivning
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function; ODM derived from: https://clinicaltrials.gov/show/NCT02014259
Länk
https://clinicaltrials.gov/show/NCT02014259
Nyckelord
Versioner (1)
- 2019-01-16 2019-01-16 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
16 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Diabetes NCT02014259
Eligibility Diabetes NCT02014259
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT02014259
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
male or female aged 18-85 years (both inclusive) at the time of signing inform consent
boolean
ID.2
Item
subject with normal renal function or renal impairment (mild, moderate, severe or end-stage renal disease requiring dialysis)
boolean
ID.3
Item
for subject with normal renal function: good general health (as judged by the investigator)
boolean
ID.4
Item
body mass index (bmi) 18.5-40.0 kg/m^2 (both inclusive)
boolean
ID.5
Item
female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods
boolean
ID.6
Item
history of crohn's disease, ulcerative colitis, or other inflammatory bowel disease
boolean
ID.7
Item
uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmhg and/or diastolic blood pressure above or equal to 100 mmhg)
boolean
ID.8
Item
any blood draw or donation of blood or plasma in excess of 400 ml within the 3 months preceding the screening visit (visit 2)
boolean
ID.9
Item
history of significant drug abuse, or a positive drug test at the screening visit (visit 2)
boolean